Dr. Kvols is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
12902 Usf Magnolia Dr
Tampa, FL 33612Phone+1 813-903-3519Fax+1 813-745-7229
Education & Training
National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 1973 - 1975
Johns Hopkins UniversityResidency, Internal Medicine, 1970 - 1973
Baylor College of MedicineClass of 1970
Certifications & Licensure
FL State Medical License 2002 - 2015
Clinical Trials
- Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer Start of enrollment: 1998 Jan 01
- Radiolabeled SMT-487 (Yttrium Y 90-DOTA-tyr3-octreotide) in Treating Patients With Refractory Small Cell Lung Cancer or Metastatic Breast Cancer Start of enrollment: 2000 Jul 01
- Avastin, Fluorouracil, Doxorubicin and Streptozocin in Locally Advanced and Metastatic Pancreatic Endocrine Tumors Start of enrollment: 2007 Aug 01
Publications & Presentations
PubMed
- 648 citationsTreatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue.Larry K. Kvols, Charles G. Moertel, Michael J. O'Connell, Allan J. Schutt, Joseph Rubin
The New England Journal of Medicine. 1986-09-11 - 130 citationsTreatment of metastatic islet cell carcinoma with a somatostatin analogue (SMS 201-995).Larry K. Kvols, Martin Buck, Charles G. Moertel, Allan J. Schutt, Joseph Rubin
Annals of Internal Medicine. 1987-08-01 - 239 citationsSomatostatin receptor-targeted radionuclide therapy of tumors: Preclinical and clinical findingsMarion de Jong, Roelf Valkema, François Jamar, Larry K. Kvols, Dik J. Kwekkeboom
Seminars in Nuclear Medicine. 2002-04-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
